NeuroStar Advanced Therapy (NeuroStar), a leader in transcranial magnetic stimulation (TMS), recently announced it has delivered more than 1.7 million treatments. These treatments—which target individuals battling with depression—having been administered to about 50,000 adults in the United States, according to the company.
The health outcomes of these treatments were recently presented at the 2018 American Psychiatric Association Annual Meeting in New York, and touched on what the company plans to do in the future to continue revolutionizing TMS treatment. It is estimated that approximately 5.5 million U.S. adults treated with antidepressants for depression do not experience remission, making alternative treatments like TMS of great import.
NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the number one clinical professional-preferred TMS treatment for consumers with Major Depressive Disorder (MDD), and is available in 49 states in the United States.
This was reported by Cision PR Newswire on May 5, 2018.
Contact Information: Neuronetics, Inc., 3222 Phoenixville Pike, Malvern, Pennsylvania 19355; (610) 640-4202; Website: www.neuronetics.com